Lee Jennifer Kayden 4

4 · RHYTHM PHARMACEUTICALS, INC. · Filed Feb 19, 2025

Form 4

Period: 2025-02-14

EVP, Head of North America

Transactions

Exercise/Conversion
Common Stock
2025-02-16+5,500→ 7,893 total
Award
Restricted Stock Units
2025-02-14+36,650→ 36,650 total
→ Common Stock (36,650 underlying)
Sale
Common Stock
2025-02-19$57.22/sh−2,035$116,443→ 5,858 total
Award
Stock Options (Right to Buy)
2025-02-14+55,000→ 55,000 total
Exercise: $56.69Exp: 2035-02-13→ Common Stock (55,000 underlying)
Exercise/Conversion
Restricted Stock Units
2025-02-16−5,500→ 16,500 total
→ Common Stock (5,500 underlying)

Footnotes (5)

[F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
[F2]The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
[F3]The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date.
[F4]The stock options were granted on February 14, 2025. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
[F5]The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date.

Documents

1 file